Revolutionary diabetes drug outperforms Metformin: Here's how it can transform health

We are in the age of advancement and medicine for better treatment to help with dangerous diseases are also getting advanced day by day. With new discovery, researchers, scientists and healthcare professionals are always in the pursuit to find, or formulate better medicines and newer approach to treat diseases. The same way, a compound HPH-15, has been developed by Kumamoto University, that reduces blood glucose and fat accumulation more effectively than metformin, with added benefits like antifibrotic properties and a safer profile. This innovation may revolutionize diabetes treatment.

The new research:

Scientists at Kumamoto University have unveiled a novel compound, HPH-15, which has dual effects: reducing blood glucose levels and combating fat accumulation. As per the researchers, this breakthrough represents a significant advancement in diabetes treatment innovation.

Type 2 diabetes is a common condition that occurs when the body doesn't use insulin properly, resulting in high blood sugar levels. The condition affects millions worldwide, and is often accompanied by complications such as fatty liver and insulin resistance, posing challenges for current treatment methods.

The research team at Kumamoto University, led by Visiting Associate Professor Hiroshi Tateishi and Professor Eiichi Araki, has identified HPH-15 as a promising alternative to existing medications like metformin.

What is HP-15?

Metformin has been the main first-line medication for the treatment of Type 2 diabetes, particularly in people who are overweight. However, the novel compound, HPH-15, with dual effects of reducing blood glucose levels and combating fat accumulation, marks a significant leap in diabetes treatment innovation. The study, published in Diabetologia, a top journal in the field of diabetes, demonstrates that HPH-15 outperforms metformin by activating AMP-activated protein kinase (AMPK)—a critical protein regulating energy balance—at lower doses. HPH-15 not only improved glucose uptake in liver, muscle, and fat cells but also significantly reduced fat accumulation in high-fat diet (HFD)-induced obese mice. Unlike metformin, HPH-15 exhibited additional antifibrotic properties, potentially addressing liver fibrosis and other complications often seen in diabetes patients.

Key findings of the research include:

Enhanced Efficacy: HPH-15 activated AMPK and promoted glucose uptake at concentrations 200 times lower than metformin.

Fat Reduction: The compound decreased subcutaneous fat by 44% and mitigated fatty liver more effectively than metformin in preclinical trials.

Safety Profile: Lactic acid production, a concern with metformin, was either comparable or lower with HPH-15, suggesting reduced risks of lactic acidosis.

These results suggest that HPH-15 could redefine diabetes management by combining glucose control with the prevention of obesity-related complications. Professor Mikako Fujita from the Faculty of Life Sciences at Kumamoto University said, “This compound holds transformative potential for diabetes treatment, offering benefits beyond blood sugar regulation.”